Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.
Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."
Our most advanced therapies in development are focused on treatments within two general areas: chronic pain in both dogs and cats, and inflammatory disease in dogs.
We believe biologic therapies offer significant advantages over current treatments in both these areas.
Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.
2-5 April 2015
British Small Animal Veterinary Association Conference, Birmingham, UK
12-14 May 2015
Bank of America Merrill Lynch 2015 Health Care Conference, Las Vegas, U.S.
3–6 June 2015
American College of Veterinary Internal Medicine Forum, IN, U.S.
23–24 June 2015
JMP Securities Life Sciences Conference, NYC, U.S.
2–4 July 2015
European College of Veterinary Surgeons Annual Scientific Meeting, Berlin, Germany
20-23 September 2015
Antibody Technologies and Therapeutics, Prato, Italy
16-20 January 2016
North American Veterinary Community conference, FL, U.S.
27 February - 5 March 2016
Veterinary Orthopedic Society of America Annual Conference, Sun Valley, ID, U.S.
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: +353 (1) 901 0339
Level 8, 31 Queen Street
P: +61 (3) 9610 4400
275 Post Street
San Francisco, CA 94108